Number Of FDA Approved Products

No definition available.

Name:	aeri_NumberOfFDAApprovedProducts
Namespace Prefix:	aeri_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Rho Kinase Inhibitor Molecules

+ References

No definition available.

+ Details

Name:	aeri_NumberOfRhoKinaseInhibitorMolecules
Namespace Prefix:	aeri_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

[Line Items] for Organization, Consolidation and Presentation of Financial Statements [Table]

+ References

No definition available.

+ Details

Name:	aeri_OrganizationConsolidationandPresentationofFinancialStatementsLineItems
Namespace Prefix:	aeri_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=aeri_DelayedDrawTermLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=aeri_ConvertibleSeniorNotesDue2024Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company (Details) rkim in Thousands	9 Months Ended
The Company (Details) rkim in Thousands	Sep. 30, 2019 USD ($) segment rkim product	May 31, 2019 USD ($)	Jul. 31, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of operating segments \| segment	1
Number U.S. FDA approved products \| product	2
Number of rho kinase inhibitor molecules owned (over) \| rkim	4
Aggregate principal amount	$ 316,250,000
Revolving Credit Facility
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Maximum borrowing capacity	200,000,000
Delayed Draw Term Loan \| Revolving Credit Facility
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Maximum borrowing capacity	200,000,000	$ 100,000,000	$ 100,000,000
Convertible Notes \| 2024 Notes
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Aggregate principal amount	$ 316,250,000
Debt instrument, interest rate percentage	1.50%